

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Resources Medical Holdings Company Limited

華潤醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

RE-DESIGNATION OF CHAIRMAN

The board (the “**Board**”) of directors (the “**Directors**”) of China Resources Medical Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Wu Ting Yuk, Anthony (“**Mr. Wu**”) has tendered his resignation as the Chairman of the Board, and remains as an independent non-executive Director due to his other engagements in business; and Mr. Song Qing (“**Mr. Song**”), the executive Director, is re-designated from the position of Vice Chairman of the Board to Chairman of the Board. The above arrangements will be effective since 23 April, 2021.

Mr. Wu and Mr. Song confirmed that they have no disagreement with the Board, and they and the Board also confirmed that there is no matter relating to the above arrangements that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board hereby expresses its gratitude to Mr. Wu for his efforts and valuable contributions to the Group during his tenure of office as the Chairman of the Board, and look forward to his great support and guidance to the business of the Group as our independent non-executive Director.

Mr. Song Qing, aged 56, joined the Group in August 2018 as an executive Director and the vice chairman. Mr. Song has extensive experiences in corporate management, and has over 30 years of experience and sophisticated background in the pharmaceutical industry. Mr. Song is currently the chairman of China Resources Healthcare Group Limited (which is principally engaged in investments in healthcare sector and operation and management of medical institutes). Mr. Song was the director of China Resources Pharmaceutical Group Limited (which is listed on the Main Board of the Stock Exchange; stock code: 3320) from May 2016 to August 2018, and also its president from June 2017 to August 2018. Mr. Song was the director of China Resources Sanjiu Medical

& Pharmaceutical Co Ltd (which is listed on Shenzhen Stock Exchange; stock code: 000999) up to August 2018, and its chairman of the board from June 2017 to August 2018. He also served as an inspection pharmacist of quality inspection department, a pharmacist in charge and the director of production department, the director of the enterprise management department and an assistant to president of Shenzhen South Pharmaceutical Factory. Mr. Song served as an assistant general manager, the director of technology center, the director of medical & pharmaceutical department of Sanjiu Enterprise.

Save as disclosed above, Mr. Song (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

Mr. Song has entered into a service agreement with the Company for the term of three years commencing from August 7, 2018 and subject to termination before expiry by either party giving not less than one month's notice in writing to the other. He is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Articles of Association. Mr. Song shall not receive any fixed salary from the Company, but he shall be entitled to the discretionary bonus at the sole and absolute discretion of the Board and the Remuneration Committee (depending on the Board's corporate goals and objectives, salaries paid by comparable companies, time commitment, responsibilities, employment conditions and performance of the Company and the individual Director). The emolument of Mr. Song was determined by the Board, upon recommendation by the Remuneration Committee with reference to the prevailing market situation and his duties and responsibilities to the Group.

As at the date of this announcement, Mr. Song is interested in a total of 400,000 shares of the Company (representing approximately 0.03% of the issued share capital of the Company), including those declared to him under the share award scheme of the Company adopted on July 7, 2014 and amended on May 25, 2015 and August 31, 2018, which 300,000 shares are unvested. Saved as disclosed above, Mr. Song does not have any interests in the Shares within the meaning of Part XV of the SFO.

Save for the information disclosed above, there is no information which is discloseable nor is Mr. Song involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters concerning Mr. Song that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Board hereby extends its warmest welcome to Mr. Song for his new appointment.

By order of the board of
China Resources Medical Holdings Company Limited
CHENG Libing
Executive Director and Chief Executive Officer

Beijing, April 23, 2021

As at the date of this announcement, the Board comprises Mr. SONG Qing, Mr. CHENG Libing, Ms. REN Yuan and Ms. FU Yanjun as executive directors; Mr. WANG Yan as non-executive directors; Mr. WU Ting Yuk, Anthony, Mr. KWONG Kwok Kong, Ms. CHIU Kam Hing Kathy and Mr. LEE Kar Chung Felix as independent non-executive directors.